Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Effectiveness and Safety of Tirzepatide Once Weekly in Adult Participants With Type 2 Diabetes During Ramadan

NCT06635057 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06635057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06635057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Effectiveness and Safety of Tirzepatide Once Weekly in Adult Participants With Type 2 Diabetes During Ramadan
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
October 11, 2024
Completion date
April 15, 2026
Enrollment
166 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes